BE739974A - - Google Patents

Info

Publication number
BE739974A
BE739974A BE739974DA BE739974A BE 739974 A BE739974 A BE 739974A BE 739974D A BE739974D A BE 739974DA BE 739974 A BE739974 A BE 739974A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE739974A publication Critical patent/BE739974A/xx

Links

Classifications

    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00Arrangement of elements for electric heating in or on furnaces
    • F27D11/08Heating by electric discharge, e.g. arc discharge
    • CCHEMISTRY; METALLURGY
    • C21METALLURGY OF IRON
    • C21CPROCESSING OF PIG-IRON, e.g. REFINING, MANUFACTURE OF WROUGHT-IRON OR STEEL; TREATMENT IN MOLTEN STATE OF FERROUS ALLOYS
    • C21C5/00Manufacture of carbon-steel, e.g. plain mild steel, medium carbon steel or cast steel or stainless steel
    • C21C5/52Manufacture of steel in electric furnaces
    • C21C5/5252Manufacture of steel in electric furnaces in an electrically heated multi-chamber furnace, a combination of electric furnaces or an electric furnace arranged for associated working with a non electric furnace
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00Arrangement of elements for electric heating in or on furnaces
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D3/00Charging; Discharging; Manipulation of charge
    • F27D3/18Charging particulate material using a fluid carrier

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
  • Furnace Details (AREA)
  • Discharge Heating (AREA)
BE739974D 1968-10-17 1969-10-08 BE739974A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR170197 1968-10-17

Publications (1)

Publication Number Publication Date
BE739974A true BE739974A (cg-RX-API-DMAC7.html) 1970-03-16

Family

ID=8655735

Family Applications (1)

Application Number Title Priority Date Filing Date
BE739974D BE739974A (cg-RX-API-DMAC7.html) 1968-10-17 1969-10-08

Country Status (10)

Country Link
US (1) US3610795A (cg-RX-API-DMAC7.html)
JP (1) JPS4829422B1 (cg-RX-API-DMAC7.html)
BE (1) BE739974A (cg-RX-API-DMAC7.html)
BR (1) BR6913348D0 (cg-RX-API-DMAC7.html)
DE (1) DE1952407B2 (cg-RX-API-DMAC7.html)
ES (1) ES372628A1 (cg-RX-API-DMAC7.html)
FR (1) FR1601438A (cg-RX-API-DMAC7.html)
GB (1) GB1252310A (cg-RX-API-DMAC7.html)
LU (1) LU59646A1 (cg-RX-API-DMAC7.html)
SE (1) SE364311B (cg-RX-API-DMAC7.html)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891427A (en) * 1972-10-12 1975-06-24 Lectromelt Corp Method for melting prereduced ore and scrap
SE378735B (cg-RX-API-DMAC7.html) * 1972-11-17 1975-09-08 Asea Ab
FR2220584B1 (cg-RX-API-DMAC7.html) * 1973-03-05 1976-05-21 Siderurgie Fse Inst Rech
US3939297A (en) * 1973-12-07 1976-02-17 Chase Brass & Copper Co., Incorporated Stoker feed system
SE7503782L (sv) * 1975-04-02 1976-10-03 Asea Ab Sett och anordning for smeltreduktion av finkornigt jernoxidhaltigt material
DE2632707C3 (de) * 1976-07-21 1983-04-07 Ernst Dipl.-Ing. 4006 Erkrath Beiersdorf Beschickungsanlage an Elektro-Lichtbogenöfen zur Zugabe von Legierungsmitteln und Zuschlagstoffen
US4133967A (en) * 1977-06-24 1979-01-09 The United States Of America As Represented By The Secretary Of The Interior Two-stage electric arc - electroslag process and apparatus for continuous steelmaking
US4447906A (en) * 1981-02-02 1984-05-08 Lectromelt Corporation Arc furnace for producing aluminum
SE8303372L (sv) * 1983-06-14 1984-12-15 Asea Ab Ugnsanordning for smeltning av metaller eller metallegeringar
AT384669B (de) * 1986-03-17 1987-12-28 Voest Alpine Ag Anlage zur herstellung von stahl aus schrott
CA1311787C (en) * 1986-06-24 1992-12-22 Masahisa Tate Method of bottom blowing operation of a steel making electric furnace
FR2705767B1 (fr) * 1993-05-27 1995-07-21 Lorraine Laminage Procédé et installation de production d'acier liquide à partir de matières ferreuses riches en matières carbonées.
DE4339226A1 (de) * 1993-11-15 1995-05-18 Mannesmann Ag Verfahren und Vorrichtung zur Wertstoffgewinnung
LU88517A7 (fr) * 1993-12-15 1996-02-01 Wurth Paul Sa Dispositif de chargement d'un four électrique
AT404841B (de) 1995-04-10 1999-03-25 Voest Alpine Ind Anlagen Anlage und verfahren zum herstellen von eisenschmelzen
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
ATE301273T1 (de) * 1999-05-18 2005-08-15 Danieli Technology Inc Elektrischer lichtbogenofen und verfahren zum kontinuierlichen chargieren
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
US20040067991A1 (en) * 2000-07-06 2004-04-08 Greig Nigel H Tetrahydrobenzothiazole analogues as neuroprotective agents
US6642002B2 (en) 2000-07-17 2003-11-04 Vanderbilt University Method of diagnosing pulmonary hypertension
EP1326892A2 (en) 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
US20040245317A1 (en) * 2001-04-06 2004-12-09 Vladimir Larionov Artificial chromosomes that can shuttle between bacteria yeast and mammalian cells
NZ532327A (en) * 2001-10-01 2005-10-28 Univ Vanderbilt Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US20040248289A1 (en) * 2001-10-04 2004-12-09 Vladimir Noskov Tandem repeat markers
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
ES2365210T3 (es) 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
EP2116604A1 (en) 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
CA2553745A1 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
EP1734982A4 (en) 2004-03-04 2009-08-05 Univ Vanderbilt Into the cell penetrating SOCS-POLYPEPTIDES THAT INHIBIT THE CYTOKININDUCED SIGNALING
US20080166323A1 (en) * 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
US20050244335A1 (en) * 2004-05-03 2005-11-03 Rinehart John J Methods and compositions related to increasing antitumor activity of chemotherapeutic agents
CA2566703A1 (en) 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
CA2564251C (en) 2004-05-21 2018-04-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
AU2005306403A1 (en) * 2004-11-18 2006-05-26 University Of Rochester Methods and compositions related to Esculentoside A
PL2289535T3 (pl) 2004-12-21 2018-12-31 Musc Foundation For Research Development Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek
EP1877074B1 (en) 2005-04-15 2013-03-27 The Government of the United States of America, as represented by the Secretary of Health and Human Services Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells
EP2371843B1 (en) 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
EP3238543B1 (en) 2005-06-07 2019-03-20 DSM Nutritional Products AG Eukaryotic microorganisms for producing lipids and antioxidants
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007047512A2 (en) 2005-10-14 2007-04-26 Musc Foundation For Research Development Inhibition of pax2 by defb1 induction as a therapy for cancer
ES2431526T3 (es) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
CA2636469A1 (en) * 2006-01-05 2007-07-19 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007092447A2 (en) 2006-02-06 2007-08-16 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
NZ597557A (en) 2006-03-02 2013-10-25 Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
JP5484049B2 (ja) 2006-07-10 2014-05-07 シナプシン ファーマシューティカルズ, インコーポレイテッド 神経学的障害を処置することおよび認知身体能力を強化することにおけるソレノプシンに関する組成物および方法ならびにその使用
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
WO2008036406A2 (en) 2006-09-21 2008-03-27 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
US20120030779A1 (en) 2007-01-18 2012-02-02 University Of Utah Research Foundtion Compositions and methods for detecting, treating, or preventing reductive stress
US9381226B2 (en) 2007-02-08 2016-07-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
EP2471925A1 (en) 2007-03-22 2012-07-04 Yale University Methods and compositions related to riboswitches that control alternative splicing
JP5671336B2 (ja) 2007-05-08 2015-02-18 バーナム インスティテュート フォー メディカル リサーチ 組織非特異的アルカリホスファターゼ阻害因子および血管石灰化を処置するためのそれらの使用
EP2155894A4 (en) 2007-05-09 2010-08-18 Burnham Inst Medical Research HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES
US8329195B2 (en) 2007-05-23 2012-12-11 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
AU2008266684A1 (en) 2007-05-29 2008-12-24 Yale University Riboswitches and methods and compositions for use of and with riboswitches
EP2166845B1 (en) 2007-06-21 2015-10-21 Musc Foundation for Research Development Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US20110081317A1 (en) * 2007-08-08 2011-04-07 University Of Rochester Enhancing Gene Transfer
US20090053192A1 (en) * 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
EP2288922B1 (en) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
US20120107331A1 (en) 2009-05-15 2012-05-03 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
WO2011088076A2 (en) 2010-01-12 2011-07-21 Yale University Structured rna motifs and compounds and methods for their use
US20130045181A1 (en) 2010-03-09 2013-02-21 Guangming Zhong Methods and Compositions for Chlamydial Antigens for Diagnosis and Treatment of Chlamydial Infection and Disease
EP2555802A1 (en) 2010-04-08 2013-02-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2012021554A1 (en) 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
JP2014501248A (ja) 2010-12-15 2014-01-20 ニューロアジュヴァンツ,インコーポレイテッド ニューロペプチド類似体、組成物、及び疼痛の治療方法
SG193500A1 (en) 2011-03-15 2013-10-30 Univ Utah Res Found Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
JP6205345B2 (ja) 2011-03-28 2017-09-27 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション ウイルス侵入の阻害に関する方法および組成物
US10766937B2 (en) 2011-09-06 2020-09-08 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
WO2014141111A1 (en) 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
JP6673200B2 (ja) 2013-07-05 2020-03-25 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 骨髄異形成症候群(mds)を治療するための可溶性cd33
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
US10189878B2 (en) 2014-09-24 2019-01-29 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
JP2018504141A (ja) 2015-01-20 2018-02-15 アドキュア バイオテクノロジーズ、 エルエルシー 非標的化アデノウイルス変異体および関連する方法
US10596247B2 (en) 2015-02-20 2020-03-24 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
WO2017040350A1 (en) 2015-08-28 2017-03-09 Navigen, Inc Compositions and methods related to inhibition of respiratory syncytial virus entry
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
IL261802B2 (en) 2016-03-16 2024-01-01 Abeome Corp Neutralizing monoclonal antibodies to IL-25 and their use
US10751340B2 (en) 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
EP4403229A3 (en) 2016-07-29 2024-08-14 Ohio State Innovation Foundation Expression of pten-long with oncolytic viruses
KR102650803B1 (ko) 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
IL268945B2 (en) 2017-02-28 2024-05-01 Univ Central Florida Res Found Inc PM21 particles to enhance NK cell migration to the bone marrow
ES2935301T3 (es) 2017-03-24 2023-03-03 Ohio State Innovation Foundation Nuevos vectores virales recombinantes adenoasociados que restringen la transducción fuera del objetivo en el hígado y usos de los mismos
WO2018183488A1 (en) 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018218151A1 (en) 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
US20200225244A1 (en) 2017-09-26 2020-07-16 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for assessing painful demyelinating and nondemyelinating diseases
US12053523B2 (en) 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
CN112135639B (zh) 2018-04-06 2023-10-20 北卡罗莱纳州立大学 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
EP3787655A4 (en) 2018-05-07 2022-08-10 Georgia State University Research Foundation Inc. Compositions and methods related to rhamnus prinoides (gesho) extract for the inhibition of polymicrobial biofilm formation
BR112020023232A2 (pt) 2018-05-16 2021-02-23 Research Institute At Nationwide Children's Hospital geração de células nk humanas expandidas e primárias de knock-out com o uso de ribonucleoproteínas cas9
CA3101971A1 (en) 2018-05-30 2019-12-05 Direct Biologics Llc A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US20210260187A1 (en) 2018-06-29 2021-08-26 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
US11331269B2 (en) 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP3847650A1 (en) 2018-09-06 2021-07-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US20220267435A1 (en) 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020093035A1 (en) 2018-11-02 2020-05-07 The Johns Hopkins University Adenoviral chimeric tdp-43 proteins
US20220136064A1 (en) 2019-02-09 2022-05-05 King Abdullah University Of Science And Technology Compositions and methods for cancer diagnosis and prognosis
EP3986446A1 (en) 2019-06-21 2022-04-27 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230002571A (ko) 2020-04-14 2023-01-05 더 리전츠 오브 더 유니버시티 오브 캘리포니아 큰 서열 범-코로나바이러스 백신 조성물
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
AU2021387970A1 (en) 2020-11-27 2023-06-29 General Nanotherapeutics Llc Methods and composition for treatment of immune-mediated diseases
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
KR102436232B1 (ko) * 2022-01-17 2022-08-25 주식회사 세명하이트 원통형 필터 제조방법 및 이에 따라 제조된 원통형 필터
US20250228940A1 (en) 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20250161360A1 (en) 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
KR102751454B1 (ko) * 2022-06-03 2025-01-10 현대제철 주식회사 전기로
KR102736561B1 (ko) * 2022-06-03 2024-12-02 현대제철 주식회사 전기로
KR102777625B1 (ko) * 2022-07-29 2025-03-11 현대제철 주식회사 전기로
KR102829902B1 (ko) * 2022-07-29 2025-07-04 현대제철 주식회사 전기로
KR102793154B1 (ko) * 2022-08-26 2025-04-07 현대제철 주식회사 전기로
KR102752443B1 (ko) * 2022-08-26 2025-01-09 현대제철 주식회사 전기로
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
US20240158490A1 (en) 2022-11-11 2024-05-16 Jeff R. Peterson Gout flare prevention methods using il-1beta blockers
KR102799788B1 (ko) * 2022-11-29 2025-04-22 현대제철 주식회사 전기로용 저취교반장치 및 이를 포함하는 전기로
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024238656A1 (en) 2023-05-15 2024-11-21 Yale Univeristy Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US848422A (en) * 1905-06-23 1907-03-26 Frank Wynne Method of maintaining or increasing the fluidity of molten or semimolten materials by means of electricity.
US1339428A (en) * 1916-03-24 1920-05-11 Ludlum Electric Furnace Corp Method of operating an electric furnace

Also Published As

Publication number Publication date
SE364311B (cg-RX-API-DMAC7.html) 1974-02-18
DE1952407A1 (de) 1970-08-20
ES372628A1 (es) 1971-11-01
DE1952407B2 (de) 1971-03-11
US3610795A (en) 1971-10-05
BR6913348D0 (pt) 1973-01-02
GB1252310A (cg-RX-API-DMAC7.html) 1971-11-03
LU59646A1 (cg-RX-API-DMAC7.html) 1970-01-12
JPS4829422B1 (cg-RX-API-DMAC7.html) 1973-09-10
FR1601438A (cg-RX-API-DMAC7.html) 1970-08-24

Similar Documents

Publication Publication Date Title
FR1601438A (cg-RX-API-DMAC7.html)
AU428130B2 (cg-RX-API-DMAC7.html)
AU5184069A (cg-RX-API-DMAC7.html)
AU6168869A (cg-RX-API-DMAC7.html)
AU429879B2 (cg-RX-API-DMAC7.html)
AU416157B2 (cg-RX-API-DMAC7.html)
AU4811568A (cg-RX-API-DMAC7.html)
AU421558B1 (cg-RX-API-DMAC7.html)
AU3789668A (cg-RX-API-DMAC7.html)
AU4744468A (cg-RX-API-DMAC7.html)
AU5758767A (cg-RX-API-DMAC7.html)
BE727765A (cg-RX-API-DMAC7.html)
BE727743A (cg-RX-API-DMAC7.html)
BE727558A (cg-RX-API-DMAC7.html)
BE727388A (cg-RX-API-DMAC7.html)
BE727215A (cg-RX-API-DMAC7.html)
BE726780A (cg-RX-API-DMAC7.html)
BE726634A (cg-RX-API-DMAC7.html)
BE726322A (cg-RX-API-DMAC7.html)
BE726210A (cg-RX-API-DMAC7.html)
BE727767A (cg-RX-API-DMAC7.html)
BE726007A (cg-RX-API-DMAC7.html)
BE725118A (cg-RX-API-DMAC7.html)
BE709496A (cg-RX-API-DMAC7.html)
AU4464266A (cg-RX-API-DMAC7.html)